Emerging paramyxoviruses: molecular mechanisms and antiviral strategies.
Emerging paramyxoviruses: molecular mechanisms and antiviral strategies.
复制标题
DOI：
10.1017/s1462399410001754
复制
发表时间：
2011-02-24
影响因子：
6.2
通讯作者：
Lee B
中科院分区：
文献类型：
--
作者：
Aguilar HC;Lee B
近年来，出现了几种感染人类的副粘病毒，包括以前未鉴定的人畜共患病。亨德拉和尼帕病毒（亨尼帕病毒（HNV））人畜共患病首次发现于1994年或1998年，分别在澳大利亚和马来西亚造成动物和人类死亡。其他副粘病毒，如梅南格病毒，蒂奥曼病毒，人偏肺病毒，禽副粘病毒-1，在人类中发病率较低，最近也被确定。虽然副粘病毒科病毒家族以前被认为是生物医学和兽医学上重要的，但最近出现的这些副粘病毒增加了我们对这个家族的关注。抗病毒药物可以被设计为针对病毒/细胞生命周期的特定重要决定因素。因此，识别和理解病毒进入、复制、组装和出芽的机制基础将在抗病毒治疗剂的开发中至关重要。本文综述了近年来发现的新出现的副粘病毒的分子机制和抗病毒策略，重点是病毒的进入和退出机制。
In recent years, several paramyxoviruses have emerged to infect humans, including previously unidentified zoonoses. Hendra and Nipah virus (henipavirus (HNV)) zoonoses were first identified in 1994 or 1998, causing deaths in animals and humans in Australia or Malaysia, respectively. Other paramyxoviruses, such as menangle virus, tioman virus, human metapneumovirus, and avian paramyxovirus-1, with less morbidity in humans, have also been recently identified. Although the Paramyxoviridae family of viruses has been previously recognized as biomedically and veterinarily important, the recent emergence of these paramyxoviruses has increased our attention to this family. Antiviral drugs can be designed to target specific important determinants of the viral/cell life cycle. Therefore, identifying and understanding the mechanistic underpinnings of viral entry, replication, assembly, and budding will be critical in the development of antiviral therapeutic agents. This review focuses on the molecular mechanisms discovered and the antiviral strategies pursued in recent years for emerging paramyxoviruses, with a concentration on viral entry and exit mechanisms.